Ethambutol (EMB) is used in combination with isoniazid and rifampicin for the treatment of tuberculosis caused by Mycobacterium tuberculosis. However, the incidence of EMB resistance is alarming. The EMB targets the cell wall arabinan biosynthesis. It is important to comprehensively understand the molecular basis of EMB to slow down the drug resistance rate of EMB. This study summarized the genes implicated in EMB resistance, regulatory network and the pharmacoproteomic effect of EMB in M. tuberculosis. Many of the genes related to EMB are implicated in membrane components, drug efflux, lipid metabolism, ribosome, and detoxification. The differential response model may help to design a novel anti-tuberculosis antibiotic.
CohenA., MathiasenV.D, SchönT., and WejseC.. 2019. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 54:1900655.
3.
Organization WH. 2013. Global Tuberculosis Report 2013. World Health Organization,, Geneva, Switzerland.
4.
SinghV., and SomvanshiP.. 2010. Toward the virtual screening of potential drugs in the homology modeled NAD+ dependent DNA ligase from Mycobacterium tuberculosis. Protein. Pept. Lett. 17:269–276.
5.
Organization, W.H. 2018. Global Tuberculosis Report 2017. Rep No 9241565055. World Health Organization,, Geneva, Switzerland.
6.
MayK.L., and GrabowiczM.. 2018. The bacterial outer membrane is an evolving antibiotic barrier. Proc. Natl. Acad. Sci. 115:8852–8854.
7.
SinghG., KumarA., MaanP., and KaurJ.. 2017. Cell wall associated factors of Mycobacterium tuberculosis as major virulence determinants: current perspectives in drugs discovery and design. Curr. Drug. Targets. 18:1904–1918.
8.
LemassuA., and DafféM.. 1994. Structural features of the exocellular polysaccharides of Mycobacterium tuberculosis. Biochem. J. 297:351–357.
9.
JacksonM.2014. The mycobacterial cell envelope—lipids. Cold Spring Harb. Perspect. Med. 4:a021105.
10.
TelentiA., PhilippW.J, SreevatsanS., et al.1997. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 3:567–570.
11.
KorkegianA., RobertsD.M, BlairR., and ParishT.. 2014. Mutations in the essential arabinosyltransferase EmbC lead to alterations in Mycobacterium tuberculosis lipoarabinomannan. J. Biol. Chem. 289:35172–35181.
12.
GoudeR., AminA.G, ChatterjeeD., and ParishT.. 2009. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53:4138–4146.
13.
GoudeR., AminA.G, ChatterjeeD., and ParishT.. 2008. The critical role of embC in Mycobacterium tuberculosis. J. Bacteriol. 190:4335–4341.
YoonJ.-H., NamJ.-S, KimK.-J, and RoY.-T.. 2013. Simple and rapid discrimination of embB codon 306 mutations in Mycobacterium tuberculosis clinical isolates by a real-time PCR assay using an LNA-TaqMan probe. J. Microbiol. Methods. 92301–306.
16.
StarksA.M., GumusbogaA., PlikaytisB.B, ShinnickT.M, and PoseyJ.E.. 2009. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53:1061–1066.
17.
XuY., JiaH., HuangH., SunZ., and ZhangZ.. 2015. Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and-resistant Mycobacterium tuberculosis clinical isolates from China. Biomed. Res. Int. 2015.
18.
CuiZ., LiY., ChengS., et al.2014. Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol. Antimicrob. Agents Chemother. 58:6837–6843.
19.
BelangerA.E., BesraG.S, FordM.E, et al. 1996. The embAB genes of, Mycobacterium avium, encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. 93: 11919–1, 1924.
20.
SrivastavaS., AyyagariA., DholeT.N, NyatiK.K, and DwivediS.K.. 2009. emb nucleotide polymorphisms and the role of embB306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int. J. Med. Microbiol. 299:269–280.
21.
LetyM.A., NairS., BercheP., and EscuyerV.. 1997. A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 41:2629–2633.
22.
ZhangN., TorrellesJ.B, McNeilM.R, et al.2003. The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region. Mol. Microbiol. 50:69–76.
23.
SreevatsanS., StockbauerK.E, PanX.I, et al.1997. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother. 41:1677–1681.
24.
MokrousovI., OttenT., VyshnevskiyB., and NarvskayaO.. 2002. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing. J. Clin. Microbiol. 40:3810–3813.
25.
GuerreroE., LemusD., YzquierdoS., et al.2013. Association between embB mutations and ethambutol resistance in Mycobacterium tuberculosis isolates from Cuba and the Dominican Republic: reproducible patterns and problems. Rev. Argent. Microbiol. 45:21–26.
26.
JaberA.-A., AhmadS., and MokaddasE.. 2009. Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Ann. Clin. Microbiol. Antimicrob. 8:2.
27.
SunQ., XiaoT., LiuH., et al.2018. Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China. Antimicrob. Agents Chemother. 62:e01279-17.
28.
KhosraviA.D., SirousM., AbdiM., and AhmadkhosraviN.. 2019. Characterization of the most common embCAB gene mutations associated with ethambutol resistance in Mycobacterium tuberculosis isolates from Iran. Infect. Drug. Resist. 12:579.
29.
PerdigãoJ., MacedoR., RibeiroA., BrumL., and PortugalI.. 2009. Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Int. J. Antimicrob. Agents. 33:334–338.
30.
ShenX., ShenG., WuJ., et al.2007. Association between embB codon 306 mutations and drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:2618–2620.
31.
BrossierF., SougakoffW., BernardC., et al. 2015. Molecular analysis of the embCAB locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France. Antimicrob. Agents Chemother. 59:4800–4808.
32.
Cuevas-CórdobaB., Juárez-EusebioD.M, Almaraz-VelascoR., Muñiz-SalazarR., Laniado-LaborinR., and Zenteno-CuevasR.. 2015. Mutation at embB codon 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59:5455–5462.
33.
MohammadiB., MohajeriP., RouhiS., and RamazanzadehR.. 2018. The relationship between embb306 and embb406 mutations and ethambutol resistant in Mycobacterium tuberculosis isolated from patiens in west of Iran. Med. J. Islam. Repub. Iran. 32:117.
34.
SafiH., LingarajuS., AminA., et al. 2013. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat. Genet. 45:1190.
35.
HeL., WangX., CuiP., et al.2015. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis. 95:149–154.
36.
Cole St, BroschR., ParkhillJ., et al.1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:537–544.
37.
MaY., SternR.J, SchermanM.S, et al.2001. Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob. Agents Chemother. 45:1407–1416.
38.
MaY., PanF., and McNeilM.. 2002. Formation of dTDP-rhamnose is essential for growth of mycobacteria. J. Bacteriol. 184:3392–3395.
39.
RamaswamyS.V., AminA.G, GökselS., et al.2000. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:326–336.
40.
AllandD., SteynA.J, WeisbrodT., AldrichK., and JacobsW.R.. 2000. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182:1802–1811.
41.
ColangeliR., HelbD., SridharanS., et al. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55:1829–1840.
42.
AllandD., KramnikI., WeisbrodT.R, et al. 1998. Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 95:13227–13232.
43.
SonnhammerELL, G. Von Heijne, and A. Krogh. A hidden Markov model for predicting transmembrane helices in protein sequences. In: Ismb, 1998, pp. 175–182.
44.
BettsJ.C., McLarenA., LennonM.G, KellyF.M, LukeyP.T, BlakemoreS.J, et al.2003. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:2903–2913.
45.
RaitioM., and WikströmM.. 1994. An alternative cytochrome oxidase of Paracoccus denitrificans functions as a proton pump. Biochim. Biophys. Acta. (BBA)-Bioenergetics. 1186:100–106.
46.
KimW.-J., SonW.S, AhnD.-H, ImH., AhnH.-C, and LeeB.-J.. 2014. Solution structure of Rv0569, potent hypoxic signal transduction protein, from Mycobacterium tuberculosis. Tuberculosis. 94:43–50.
47.
SpiveyV.L., WhalanR.H, HirstE.M.A, SmerdonS.J, and BuxtonR.S.. 2013. An attenuated mutant of the Rv1747 ATP-binding cassette transporter of Mycobacterium tuberculosis and a mutant of its cognate kinase, PknF, show increased expression of the efflux pump-related iniBAC operon. FEMS Microbiol. Lett. 347:107–115.
48.
HaoP., Shi-LiangZ., JuL., et al.2011. The role of ABC efflux pump, Rv1456c-Rv1457c-Rv1458c, from Mycobacterium tuberculosis clinical isolates in China. Folia. Microbiol. (Praha). 56:549–553.
49.
GuptaA.K., ReddyV.P, LavaniaM., et al.2010. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian. J. Med. Res. 132:176–188.
50.
ŞahinF, KiyanM. 2017. The roles of efflux systems in extensively drug-resistant Mycobacterium Tuberculosis. Turkish. J. Mol. Biol. Biotechnol. 2:71–81.
51.
PawarA., JhaP., KonwarC., ChaudhryU., ChopraM., and SalujaD.. 2019. Ethambutol targets the glutamate racemase of Mycobacterium tuberculosis—an enzyme involved in peptidoglycan biosynthesis. Appl. Microbiol. Biotechnol. 103:843–851.
52.
SenguptaS., GhoshS., and NagarajaV.. 2008. Moonlighting function of glutamate racemase from Mycobacterium tuberculosis: racemization and DNA gyrase inhibition are two independent activities of the enzyme. Microbiology. 154:2796–2803.
53.
Fisher, S.L. 2008. Glutamate racemase as a target for drug discovery. Microb. Biotechnol. 1:345–360.
54.
CanettiG., FoxW., al KhomenkoA., et al.1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 41:21.
55.
LawsonL., EmenyonuN., AbdurrahmanS.T, et al.2013. Comparison of Mycobacterium tuberculosis drug susceptibility using solid and liquid culture in Nigeria. BMC Res. Notes. 6:215.
56.
RitterC., LuckeK., SirgelF.A, et al.2014. Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains. J. Clin. Microbiol. 52:940–946.
57.
Molina-MoyaB., LacomaA., PratC., et al.2015. AID TB resistance line probe assay for rapid detection of resistant Mycobacterium tuberculosis in clinical samples. J. Infect. 70:400–408.
58.
LacomaA., Garcia-SierraN., PratC., et al.2012. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J. Clin. Microbiol. 50:30–36.
59.
FengY., LiuS., WangQ., et al. 2013. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One. 8:e5, 5292.
60.
MunirS., MahmoodN., ShahidS., and KhanM.I. 2017. Molecular detection of isoniazid, rifampin and ethambutol resistance to M. tuberculosis and M. bovis in multidrug resistant tuberculosis (MDR-TB) patients in Pakistan. Microb. Pathog. 110:262–274.
61.
EsfahaniB.N., ZarkeshF.S, YazdiH.R, and RadaeeT.. 2016. Detection of embB gene mutations in EMB-resistant Mycobacterium tuberculosis isolates from Isfahan province by PCR-SSCP and direct sequencing. Jundishapur. J. Microbiol. 9.
62.
AhmadS., MokaddasE., and JaberA.-A.. 2004. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol. Cell Probes. 18:299–306.
63.
NguyenA.T.N., Anton-LeberreV., NguyenV.A.T, and BañulsA.-L.. 2019. Molecular diagnosis of drug-resistant tuberculosis: a literature review. Front Microbiol. 10:794.
64.
JiaL., CowardL., GormanG.S, NokerP.E, and TomaszewskiJ.E.. 2005. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N′-(2-adamantyl) ethane-1, 2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J. Pharmacol. Exp. Ther. 315:905–911.
65.
CarlssonF., JoshiS.A, RangellL., and BrownE.J.. 2009. Polar localization of virulence-related Esx-1 secretion in mycobacteria. PLoS Pathog. 5.
66.
XuY., YangE., HuangQ., et al.2015. PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2. J. Mol. Med. 93:645–662.
67.
WilsonM., DeRisiJ., KristensenH.-H, et al. 1999. Exploring drug-induced alterations in gene expression in, Mycobacterium tuberculosis, by microarray hybridization. Proc. Natl. Acad. Sci. 96: 12833–1, 2838.
68.
Ghiraldi-LopesL.D., Campanerut-SáP.A.Z, EvaristoG.P.C, et al.2019. New insights on ethambutol targets in Mycobacterium tuberculosis. Infect. Disord. Targets (Formerly Curr. Drug Targets-Infectious Disord. 19:73–80.
69.
Campanerut-SáP.A.Z., Ghiraldi-LopesL.D, MeneguelloJ.E, et al.2016. Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis. Future Microbiol. 11:1123–1132.
70.
HughesM.A., SilvaJ.C, GeromanosS.J, and TownsendC.A.. 2006. Quantitative proteomic analysis of drug-induced changes in mycobacteria. J. Proteome. Res. 5:54–63.
71.
WagnerT., BellinzoniM., WehenkelA., O'HareH.M, and AlzariP.M.. 2011. Functional plasticity and allosteric regulation of α-ketoglutarate decarboxylase in central mycobacterial metabolism. Chem. Biol. 18:1011–1020.
72.
VenugopalA., BrykR., ShiS., et al.2011. Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host. Microbe. 9:21–31.
73.
DeyS., BurtonR.L, GrantG.A, and SacchettiniJ.C.. 2008. Structural analysis of substrate and effector binding in Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase. Biochemistry. 47:8271–8282.
74.
Wright, G.D. 2007. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat. Rev. Microbiol. 5:175–186.
75.
PadiadpuJ., VashishtR., and ChandraN.. 2010. Protein–protein interaction networks suggest different targets have different propensities for triggering drug resistance. Syst. Synth. Biol. 4:311–322.
76.
ZhangS.-L., QiH., QiuD.-L, et al.2007. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates recovered from central China. Biochem. Genet. 45:281–290.
77.
RamanK., and ChandraN.. 2008. Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance. BMC Microbiol. 8:234.
78.
ShenoiS., and FriedlandG.. 2009. Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu. Rev. Med. 60:307–320.
79.
SchubertK., SiegerB., MeyerF., et al.2017. The antituberculosis drug ethambutol selectively blocks apical growth in CMN group bacteria. mBio, 8, DOI: 10.1128/mBio.02213-16.
80.
ZhouX., Rodriguez-RiveraF.P, LimH.C, et al.2019. Sequential assembly of the septal cell envelope prior to V snapping in Corynebacterium glutamicum. Nat. Chem. Biol. 15:221–231.
81.
LimH.C., SherJ.W, Rodriguez-RiveraF.P, FumeauxC., BertozziC.R, and BernhardtT.G.. 2019. Identification of new components of the RipC-FtsEX cell separation pathway of Corynebacterineae. PLoS Genet. 15.
82.
YangM., ZhangL., TaoH-L, et al.2019. OxiR specifically responds to isoniazid and regulates isoniazid susceptibility in mycobacteria. FEMS Microbiol. Lett. 366:fnz109.
83.
ZhuC., LiuY., HuL., YangM., and HeZ.-G.. 2018. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. J. Biol. Chem. 293:16741–16750.
84.
ZhangL., ZhaoY., GaoY., et al.2020. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science (80-). 368:1211–1219.
85.
MengQ., LuoH., LiuY., LiW., ZhangW., and YaoQ.. 2009. Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents. Bioorg. Med. Chem. Lett. 19:2808–2810.
86.
ZhangX., HuY., ChenS., et al.2009. Synthesis and evaluation of (S, S)-N, N′-bis-[3-(2, 2′, 6, 6′-tetramethylbenzhydryloxy)-2-hydroxy-propyl]-ethylenediamine (S2824) analogs with anti-tuberculosis activity. Bioorg. Med. Chem. Lett. 19:6074–6077.
87.
LeeR.E., ProtopopovaM., CrooksE., SlaydenR.A, TerrotM., and BarryC.E.. 2003. Combinatorial lead optimization of [1, 2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5:172–187.
88.
RazafimahefaD., RalambomananaD.A, HammoucheL., et al.2005. Synthesis and antimycobacterial activity of ferrocenyl ethambutol analogues and ferrocenyl diamines. Bioorg. Med. Chem. Lett. 15:2301–2303.
89.
del OlmoE., Molina-SalinasG.M, BiniE.I, et al.2016. Efficacious in vitro and in vivo effects of dihydrosphingosine–ethambutol analogues against susceptible and multi-drug-resistant Mycobacterium tuberculosis. Arch. Med. Res. 47:262–270.
90.
SinghA., SomvanshiP., and GroverA.. 2019. Drug repurposing against arabinosyl transferase (EmbC) of Mycobacterium tuberculosis: Essential dynamics and free energy minima based binding mechanics analysis. Gene. 693:114–126.
91.
KumarA., AlamA., GroverS., et al.2019. Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention. NPJ Biofilms. Microbiomes. 5:1–11.
